Combining treat-to-target principles and shared decision-making: International expert consensus-based recommendations with a novel concept for minimal disease activity criteria in atopic dermatitis

Atopic Dermatitis

Targeted Combined Endpoint Improvement in Patient and Disease Domains in Atopic Dermatitis: A Treat-to-Target Analysis of Adults with Moderate-to-Severe Atopic Dermatitis Treated with Upadacitinib

Acta Derm Venereol

Kwatra SG, De Bruin-Weller M, Silverberg JI, Lio P, Deleuran M, Aydin H, Calimlim BM, Lane MC, Liu Y, Ofori S, Weidinger S

doi: 10.2340/actadv.v104.18452

Juvenile Idiopathic Arthritis

Factors for Consideration by Pediatric Rheumatologists When Scoring the Physician Global Assessment (PhGA) of Disease Activity in Juvenile Idiopathic Arthritis: First Step Toward an Internal Consensus

Arthritis Care Res (Hoboken)

Tarkiainen M, Balay-Dustrude E, Consolaro A, Morgan EM, Ruperto N, Rypdal V, Backström M, Vähäsalo P, Gottlieb BS, Paediatric Rheumatology International Trials Organisation, and the Pediatric Rheumatology Care & Outcomes Improvement Network and the PhGA consensus task force, For the Pediatric Rheumatology European Society (PRES) JIA working party

doi: 10.1002/acr.25447

Osteoarthritis

Utilising Adaptive Choice-Based Conjoint Approach to Facilitate Shared Decision-Making in Osteoarthritis Management: A Patient Perception Study

Arthritis Care Res (Hoboken)

Al-Omari B, Farhat J, Odeh M, Khan M, Grancharov H, Abu Zahr Z, Hanna S, Alrahoomi A

doi: 10.1002/acr.25429

Further Publications Immunology

Efficacy of Janus kinase inhibitors in immune-mediated inflammatory diseases-a systematic literature review informing the 2024 update of an international expert consensus statement

Ann Rheum Dis

Konzett V, Smolen JS, Nash P, Aletaha D, Winthrop K, Dörner T, Fleischmann R, Tanaka Y, Primdahl J, Baraliakos X, McInnes IB, Trauner M, Sattar N, de Wit M, Schoones JW, Kerschbaumer A

doi: 10.1016/j.ard.2025.01.023

Psoriatic Arthritis

Association of achieving clinical disease control criteria and patient-reported outcomes in bimekizumab-treated patients with active psoriatic arthritis: results from two phase III studies

Ther Adv Musculoskelet Dis

Kristensen LE, Tillett W, Nash P, Coates LC, Mease PJ, Ogdie A, Gisondi P, Ink B, Prickett AR, Bajracharya R, Taieb V, Lyris N, Lambert J, Walsh JA

doi: 10.1177/1759720X241288071

Further Publications Immunology

Safety of Janus kinase inhibitors in immune-mediated inflammatory diseases-a systematic literature review informing the 2024 update of an international expert consensus statement

Ann Rheum Dis

Konzett V, Smolen JS, Nash P, Winthrop K, Aletaha D, Dörner T, Fleischmann R, Tanaka Y, Primdahl J, Baraliakos X, McInnes IB, Trauner M, Sattar N, de Wit M, W Schoones J, Kerschbaumer A

doi: 10.1016/j.ard.2025.01.024

Atopic Dermatitis

Measuring Signs of Atopic Dermatitis in Clinical Practice: A HOME-CP Consensus Statement

JAMA Dermatol

Jacobson ME, Leshem YA, Apfelbacher C, Spuls PI, Gerbens LAA, Thomas KS, Williams HC, Katoh N, Howells L, Schmitt J, Deckert S, Seshadri R, Simpson EL, Harmonising Outcome Measures for Eczema (HOME) initiative

doi: 10.1001/jamadermatol.2024.1162

Further Publications Immunology

Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study

Lancet

Ferrante M, D'Haens G, Jairath V, Danese S, Chen M, Ghosh S, Hisamatsu T, Kierkus J, Siegmund B, Bragg SM, Crandall W, Durand F, Hon E, Lin Z, Lopes MU, Morris N, Protic M, Carlier H, Sands BE, VIVID Study Group

doi: 10.1016/S0140-6736(24)01762-8

Atopic Dermatitis

Onset and Long-Term Maintenance of Optimal Itch Response in Adult Patients with Moderate-to-Severe Atopic Dermatitis Treated with Dupilumab: Post Hoc Analysis from Two Phase 3 Trials

Adv Ther

Ständer S, Yosipovitch G, Simpson EL, Kim BS, Kabashima K, Thaçi D, Metz M, Chen Z, Hagen S, Bastian M

doi: 10.1007/s12325-025-03124-8

Related content

Targeted Combined Endpoint Improvement in Patient and Disease Domains in Atopic Dermatitis: A Treat-to-Target Analysis of Adults with Moderate-to-Severe Atopic Dermatitis Treated with Upadacitinib

Factors for Consideration by Pediatric Rheumatologists When Scoring the Physician Global Assessment (PhGA) of Disease Activity in Juvenile Idiopathic Arthritis: First Step Toward an Internal Consensus

Utilising Adaptive Choice-Based Conjoint Approach to Facilitate Shared Decision-Making in Osteoarthritis Management: A Patient Perception Study

Efficacy of Janus kinase inhibitors in immune-mediated inflammatory diseases-a systematic literature review informing the 2024 update of an international expert consensus statement

Association of achieving clinical disease control criteria and patient-reported outcomes in bimekizumab-treated patients with active psoriatic arthritis: results from two phase III studies

Safety of Janus kinase inhibitors in immune-mediated inflammatory diseases-a systematic literature review informing the 2024 update of an international expert consensus statement

Measuring Signs of Atopic Dermatitis in Clinical Practice: A HOME-CP Consensus Statement

Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study

Onset and Long-Term Maintenance of Optimal Itch Response in Adult Patients with Moderate-to-Severe Atopic Dermatitis Treated with Dupilumab: Post Hoc Analysis from Two Phase 3 Trials